Tools

LEADER 04652cam a22006018i 4500

001 ssj0002536527;

003 WaSeSS;

005 20240912175819.0;

006 m d ;

007 cr n ;

008 210317s2021 enk sb 001 0 eng d;

010 a| 2021012648;

020 a| 9781009009898q| (paperback);

020 z| 9781009002103q| (ebook);

035 a| (WaSeSS)ssj0002536527;

040 a| DNLM/DLCb| engc| DLCd| WaSeSS;

042 a| pcc;

049 a| EREEa| NEHH;

050 00 a| RM333.5;

060 00 a| QV 77.9;

082 00 a| 615.7/8822| 23;

084 a| MED102000a| MED1020002| bisacsh;

100 1 a| Meyer, Jonathan M.,d| 1962-=| ^A938056;

245 14 a| The clinical use of antipsychotic plasma levelsh| [electronic resource] /c| Jonathan M Meyer, Stephen M Stahl ; with illustrations by Nancy Munter.;

260 a| Cambridge ;a| New York, NY :b| Cambridge University Press,c| 2021.;

263 a| 2110;

300 a| pages cm;

490 1 a| Stahl's handbooks;

504 a| Includes bibliographical references and index.;

505 0 a| Sampling times for oral and long acting injectable agents -- The therapeutic threshold and the point of futility -- Level interpretation including laboratory reporting issues, responding to high plasma issues, responding to high plasma levels, special situations (hepatic dysfunction, renal dysfunction and hemodialysis, bariatric surgery) -- Tracking oral antipsychotic adherence -- What is an adequate antipsychotic trial-using plasma levels to optimize psychiatric response and tolerability -- Important concepts about first generation antipsychotics -- Haloperidol and haloperidol decanoate -- Fluphenazine and fluphenazine decanoate -- Perphenazine and perphenazine decanoate -- Zuclopenthixol and zuclopenthixol decanoate; flupenthixol and flupenthixol decanoate -- Chlorpromazine, loxapine, thiothixene, trifluoperazine -- Important concepts about second generation antipsychotics -- Clozapine -- Risperidone oral and long acting injectable, paliperidone oral and long acting injectable -- Olanzapine and olanzapine pamoate -- Aripiprazole, aripiprazole monohydrate and aripiprazole lauroxil -- Amisulpride, asenapine, lurasidone, brexpiprazole, cariprazine.;

506 a| Available only to authorized users.;

520 a| "The use of antipsychotics to treat schizophrenia is fraught with many layers of complexity, as prescribers try to tailor the pharmacodynamic properties of an agent to a specific patient based primarily on subjective response. Variations in drug metabolism related to genetic polymorphisms, or to medication or environmental exposures (e.g. smoking), and variable adherence with oral medications lead to scenarios that confound even seasoned clinicians. Excluding the realization that up to one-third of schizophrenia patients may not respond adequately to non-clozapine antipsychotics, 60 years of antipsychotic research has demonstrated that dose is a poor correlate of response likelihood, whereas plasma drug levels represent the best clinically available tool that quantifies the relationship between drug exposure and central nervous system (CNS) activity.[1] The classic equation by psychopharmacologist Sheldon Preskorn illustrates the variables involved in clinical drug response (Figure 1.1)"--c| Provided by publisher.;

538 a| Mode of access: World Wide Web;

650 12 a| Antipsychotic Agentsx| blood=| ^A931994;

650 12 a| Dose-Response Relationship, Drug=| ^A920467;

650 22 a| Antipsychotic Agentsx| therapeutic use=| ^A929558;

650 22 a| Dose-Response Relationship, Drug=| ^A920467;

650 22 a| Psychotic Disordersx| drug therapy=| ^A950617;

650 22 a| Schizophreniax| drug therapy=| ^A923199;

650 7 a| MEDICAL / Mental Health2| bisacsh;

655 0 a| Electronic books.=| ^A491897;

700 1 a| Stahl, Stephen M.,d| 1951-=| ^A930023;

830 0 a| Stahl's handbooks.?| UNAUTHORIZED;

856 40 z| Full text available from Cambridge: Stahl Onlineu| https://go.openathens.net/redirector/ecu.edu?url=https%3A%2F%2Fdoi.org%2F10.1017%2F9781009002103;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 5830259;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5830259-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 6/16/2022x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5830259-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 6/16/2022x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5830259-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 6/16/2022x| EBOOKz| JERESOURCE;

The clinical use of antipsychotic plasma levels / Jonathan M Meyer, Stephen M Stahl ; with illustrations by Nancy Munter.

Author/creator	Meyer, Jonathan M., 1962-
Other author	Stahl, Stephen M., 1951-
Format	Electronic
Publication Info	Cambridge ; New York, NY : Cambridge University Press, 2021.
Description	pages cm
Supplemental Content	Full text available from Cambridge: Stahl Online
Subjects	Antipsychotic Agents--blood. Dose-Response Relationship, Drug Antipsychotic Agents--therapeutic use. Dose-Response Relationship, Drug Psychotic Disorders--drug therapy. Schizophrenia--drug therapy.

Series	Stahl's handbooks Stahl's handbooks. UNAUTHORIZED
Contents	Sampling times for oral and long acting injectable agents -- The therapeutic threshold and the point of futility -- Level interpretation including laboratory reporting issues, responding to high plasma issues, responding to high plasma levels, special situations (hepatic dysfunction, renal dysfunction and hemodialysis, bariatric surgery) -- Tracking oral antipsychotic adherence -- What is an adequate antipsychotic trial-using plasma levels to optimize psychiatric response and tolerability -- Important concepts about first generation antipsychotics -- Haloperidol and haloperidol decanoate -- Fluphenazine and fluphenazine decanoate -- Perphenazine and perphenazine decanoate -- Zuclopenthixol and zuclopenthixol decanoate; flupenthixol and flupenthixol decanoate -- Chlorpromazine, loxapine, thiothixene, trifluoperazine -- Important concepts about second generation antipsychotics -- Clozapine -- Risperidone oral and long acting injectable, paliperidone oral and long acting injectable -- Olanzapine and olanzapine pamoate -- Aripiprazole, aripiprazole monohydrate and aripiprazole lauroxil -- Amisulpride, asenapine, lurasidone, brexpiprazole, cariprazine.
Abstract	"The use of antipsychotics to treat schizophrenia is fraught with many layers of complexity, as prescribers try to tailor the pharmacodynamic properties of an agent to a specific patient based primarily on subjective response. Variations in drug metabolism related to genetic polymorphisms, or to medication or environmental exposures (e.g. smoking), and variable adherence with oral medications lead to scenarios that confound even seasoned clinicians. Excluding the realization that up to one-third of schizophrenia patients may not respond adequately to non-clozapine antipsychotics, 60 years of antipsychotic research has demonstrated that dose is a poor correlate of response likelihood, whereas plasma drug levels represent the best clinically available tool that quantifies the relationship between drug exposure and central nervous system (CNS) activity.[1] The classic equation by psychopharmacologist Sheldon Preskorn illustrates the variables involved in clinical drug response (Figure 1.1)"-- Provided by publisher.
Bibliography note	Includes bibliographical references and index.
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Genre/form	Electronic books.
LCCN	2021012648
ISBN	9781009009898 (paperback)
ISBN	(ebook)

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

The clinical use of antipsychotic plasma levels / Jonathan M Meyer, Stephen M Stahl ; with illustrations by Nancy Munter.

Click here for more information about this title

Availability